Latest Pharmaceutical Earnings News

Page 1 of 1

CSL’s Profit Plummets 80% Amid $2 Billion Restructuring and Impairments

CSL Limited reported a sharp 80% drop in net profit for the half year ended December 2025, driven by significant restructuring and impairment charges, yet maintained its growth guidance and dividend payout.

Ada Torres

11 Feb 2026

Neuren’s DAYBUE Royalties Climb 16% as Patient Numbers Hit Record High

Neuren Pharmaceuticals reports a 16% rise in Q2 2025 royalties driven by Acadia’s DAYBUE sales growth and expanding patient base in the US. Full-year sales guidance remains strong with European market entry on the horizon.

Victor Sage

7 Aug 2025

Neuren’s DAYBUE Sales Climb 11% as European Launch Nears

Neuren Pharmaceuticals reports a robust 11% rise in DAYBUE™ US net sales for Q1 2025, alongside a 17% jump in royalty income, setting the stage for an anticipated European market entry in early 2026.

Victor Sage

8 May 2025